Related Experiment Video
Updated: Mar 14, 2026
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
SHP2 phosphatase as a novel therapeutic target for melanoma treatment
Ruo-Yu Zhang1, Zhi-Hong Yu1, Lifan Zeng2
1Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA.
Abstract:
Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.
Insights
Elevated SHP2 protein levels correlate with aggressive melanoma and poor prognosis. Targeting SHP2 with inhibitor 11a-1 effectively reduced melanoma growth and metastasis in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Melanoma is an aggressive cancer with limited treatment options.
- Drug resistance and lack of durable responses necessitate new therapeutic targets.
- SHP2 (PTPN11) is a protein tyrosine phosphatase implicated in various cancers.
Purpose of the Study:
- To investigate the role of SHP2 in melanoma progression.
- To evaluate the therapeutic potential of SHP2 inhibition in melanoma.
Main Methods:
- Analysis of SHP2 expression in melanoma tissues.
- In vitro studies on melanoma cell lines assessing viability, motility, and growth.
- In vivo studies using xenograft models of melanoma.
- Pharmacological inhibition of SHP2 using inhibitor 11a-1.
Main Results:
- High SHP2 expression is linked to melanoma metastasis and poor prognosis.
- SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth via ERK1/2 and AKT pathways.
- SHP2 inhibitor 11a-1 reduced melanoma cell proliferation, migration, and colony formation.
- SHP2 inhibitor 11a-1 suppressed xenografted melanoma tumor growth by decreasing proliferation and increasing apoptosis.
Conclusions:
- SHP2 is a novel therapeutic target for melanoma.
- SHP2 inhibitors represent a promising new class of drugs for melanoma treatment.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...